Pharmala Biotech Holdings Inc.
Canadian Securities ExchangeTotal Valuation
Pharmala Biotech Holdings Inc. carries a market capitalization of 15.79M, placing it among publicly traded companies globally.
| Market Cap | 15.79M |
| Enterprise Value | N/A |
Share Statistics
Pharmala Biotech Holdings Inc. currently has 108.92M shares outstanding.
| Shares Outstanding | 108.92M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 11.47, and the price-to-book ratio stands at -167.78.
| PE Ratio | N/A |
| PS Ratio | 11.47 |
| PB Ratio | -167.78 |
| P/TBV Ratio | 24.64 |
| P/FCF Ratio | -11.65 |
| P/OCF Ratio | -11.11 |
Financial Position
Pharmala Biotech Holdings Inc. maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.42 |
| Quick Ratio | 1.01 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -1,141.20 |
| Return on Assets (ROA) | -56.71 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.27 |
Stock Price Statistics
Pharmala Biotech Holdings Inc.'s stock has gained approximately 45% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.12.
| Beta (5Y) | N/A |
| 52-Week Price Change | 45% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.12 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Pharmala Biotech Holdings Inc. generated 889,568.00 in revenue and converted that into -1.63M in net income, yielding earnings per share of -0.02. EBITDA reached -1.47M, while operating income came in at -1.59M.
| Revenue | 889,568.00 |
| Gross Profit | 788,664.00 |
| Operating Income | -1.59M |
| Pretax Income | -1.63M |
| Net Income | -1.63M |
| EBITDA | -1.47M |
| EBIT | -1.59M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Total book value stands at -60,809.00, with working capital of 411,732.00 providing operational flexibility.
| Cash & Cash Equivalents | 564,709.00 |
| Total Debt | N/A |
| Net Debt | -113,244.00 |
| Equity (Book Value) | -60,809.00 |
| Book Value Per Share | 0.00 |
| Working Capital | 411,732.00 |
Cash Flow
Pharmala Biotech Holdings Inc. produced -918,372.00 in operating cash flow over the past twelve months. After subtracting -42,674.00 in capital expenditures, free cash flow totaled -961,046.00 - equivalent to -0.01 per share.
| Operating Cash Flow | -918,372.00 |
| Capital Expenditures | -42,674.00 |
| Free Cash Flow | -961,046.00 |
| FCF Per Share | -0.01 |
Margins
Pharmala Biotech Holdings Inc. operates with a gross margin of 88.66, reflecting its pricing power and cost economics. The operating margin of -179.04 and net profit margin of -183.55 provide insight into operational efficiency.
| Gross Margin | 88.66 |
| Operating Margin | -179.04 |
| Pretax Margin | -183.55 |
| Profit Margin | -183.55 |
| EBITDA Margin | -165.79 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.03 |
| FCF Yield | -8.58 |
Scores
Pharmala Biotech Holdings Inc. posts an Altman Z-Score of -4.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -4.45 |